Start with landmark trials
Large, well-documented trials with posted estimates, confidence intervals and publications.
- PEOPLEComplete statistical analysis of the PEOPLE phase 3 trial of post-exposure prophylaxis for leprosy in the Comoros and Madagascar, including trial design, incidence rate ratios, mixed-effects methodology, confidence intervals, and interpretation.
- ONTARGETAn independent statistical analysis of ONTARGET and its companion trial TRANSCEND: Cox hazard ratios for telmisartan, ramipril and their combination, the non-inferiority margin of 1.13, renal outcomes in diabetic nephropathy, and serious…
- ENGAGE AF-TIMI 48Independent statistical analysis of ENGAGE AF-TIMI 48, evaluating edoxaban versus warfarin for stroke and systemic embolic events in patients with atrial fibrillation.
- ARISTOTLEIndependent statistical analysis of ARISTOTLE (NCT00412984), including trial design, time-to-event endpoints, Cox proportional-hazards methodology, hazard ratios, confidence intervals, safety results, and statistical interpretation.
- ODYSSEY OUTCOMESComplete statistical analysis of ODYSSEY OUTCOMES, the randomized phase 3 trial of alirocumab versus placebo after acute coronary syndrome, including time-to-event endpoints, hazard ratios, stratified log-rank testing, multiplicity, safety, and statistical interpretation.
- SPIRE-1An independent statistical analysis of SPIRE-1 (NCT01975376), the terminated phase 3 placebo-controlled trial of bococizumab for prevention of major cardiovascular events: stratified Cox hazard ratios, MMRM and ANCOVA lipid analyses, multiplicity and…
Explore by statistical method
Every trial page explains the methods behind its results. Pick a method to see it applied.
Browse by therapeutic area
Oncology
Phase 2 and 3 cancer trials, dominated by time-to-event endpoints: overall and progression-free survival, hazard ratios, stratified log-rank tests, and response rates.
Infectious Disease
Trials of vaccines, antivirals, antibiotics and prevention strategies, from HIV and hepatitis to influenza and COVID-19, with many non-inferiority designs.
Cardiovascular
Large outcome trials in heart failure, atrial fibrillation, coronary disease and stroke prevention, built around composite time-to-event endpoints.
Neurology
Trials in multiple sclerosis, Alzheimer's disease, migraine, epilepsy, Parkinson's disease and stroke, with relapse-rate, longitudinal and time-to-event analyses.
Psychiatry & Mental Health
Trials in depression, schizophrenia, bipolar disorder, anxiety and substance use, typically analyzed with mixed models for repeated measures.
Endocrinology & Metabolism
Diabetes, obesity and metabolic trials, from HbA1c and weight endpoints analyzed with ANCOVA and MMRM to cardiovascular outcome trials.
Respiratory
Asthma, COPD, pulmonary fibrosis and cystic fibrosis trials, including exacerbation-rate endpoints analyzed with negative binomial and Poisson models.
Nephrology & Urology
Chronic kidney disease, dialysis and urologic trials, with kidney-function slopes and composite renal outcomes.
Hematology
Trials in anemia, hemophilia, sickle cell disease and blood cancers, spanning response rates, bleeding rates and survival endpoints.
Immunology & Rheumatology
Rheumatoid arthritis, psoriasis, lupus and allergic-disease trials, often built on responder endpoints and categorical analyses.
Gastroenterology & Hepatology
Inflammatory bowel disease, liver disease and other digestive-disorder trials, with remission endpoints and categorical comparisons.
Dermatology
Psoriasis, atopic dermatitis and other skin-disease trials, typically analyzed as responder proportions with stratified tests.
Ophthalmology
Macular degeneration, diabetic eye disease and glaucoma trials, often with continuous visual-acuity endpoints and non-inferiority designs.
Women's Health & Pregnancy
Trials in pregnancy, contraception and gynecologic conditions, spanning binary outcomes and time-to-event analyses.
Musculoskeletal
Osteoporosis, osteoarthritis and bone-disease trials, with fracture-risk time-to-event analyses and bone-density endpoints.
Critical Care & Injury
Sepsis, trauma, shock and critical-illness trials, typically centered on mortality and organ-support outcomes.
Other
Trials that do not fall into a single therapeutic area, including healthy-volunteer and multi-condition studies.